GSK to produce 1 bln doses of adjuvant vaccine booster in 2021

British drugmaker GlaxoSmithKline Plc will expand production of vaccine efficacy boosters, or adjuvants, to produce 1 billion doses in 2021 for use in shots for COVID-19, the company said on Thursday.

The company added it was in talks with governments on backing for the program, which would effectively allow the expansion of the scale of production of future successful vaccines for the disease caused by the novel coronavirus.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)